February 27, 2020 / 12:51 PM / a month ago

BRIEF-Intellia Therapeutics Announces Q4 Loss Per Share $0.57

Feb 27 (Reuters) - Intellia Therapeutics Inc:

* INTELLIA THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS

* INTELLIA THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.57

* INTELLIA THERAPEUTICS INC - QTRLY COLLABORATION REVENUE $10.9 MILLION VERSUS $7.9 MILLION

* INTELLIA THERAPEUTICS INC - ON TRACK TO SUBMIT IND APPLICATION FOR NTLA-2001 FOR TREATMENT OF TRANSTHYRETIN AMYLOIDOSIS IN MID-2020

* INTELLIA THERAPEUTICS INC - PLANS TO SUBMIT IND APPLICATION FOR NTLA-5001 FOR TREATMENT OF ACUTE MYELOID LEUKEMIA IN FIRST HALF OF 2021

* INTELLIA THERAPEUTICS INC - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $284.5 MILLION AS OF DEC. 31, 2019 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below